Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 5/20 | 0.45 |
| ▸ | STAT3 | P40763 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | CRHBP | P24387 | 2/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.36 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.35 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4756407 | 0.89 | STAT3 (0.51) | GRM4STAT3MEN1KMT2ACRHBP | |
| SCHEMBL4757140 | 0.82 | GRM4 (0.45) | GRM4STAT3MEN1KMT2AMAPT | |
| SCHEMBL4757028 | 0.80 | NPC1 (0.46) | MEN1KMT2AMAPTALDH1A1NPC1 | |
| SCHEMBL19978237 | 0.79 | ALDH1A1 (0.54) | GRM4MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL4756409 | 0.79 | ALDH1A1 (0.57) | GRM4STAT3MEN1KMT2ACRHBP | |
| SCHEMBL4756651 | 0.73 | GRM4 (0.49) | GRM4STAT3MEN1KMT2ACRHBP | |
| SCHEMBL4756878 | 0.73 | STAT3 (0.44) | GRM4STAT3MEN1KMT2ACRHBP | |
| SCHEMBL4756965 | 0.73 | FFAR2 (0.48) | GRM4STAT3MEN1KMT2ACRHBP | |
| SCHEMBL16918852 | 0.72 | GRM4 (0.42) | GRM4STAT3MEN1KMT2ACRHBP | |
| SCHEMBL31426452 | 0.72 | STAT3 (0.58) | GRM4STAT3MEN1KMT2ACRHBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2178852-B9 | ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS | ROMARK LAB LC (US) | 2016-06-22 | — | — | EP | disclosed |
| EP-2178852-B1 | ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS | ROMARK LAB LC (US) | 2015-07-22 | — | — | EP | disclosed |
| US-8895752-B2 | Alkylsulfonyl-substituted thiazolide compounds | ROMARK LABORATORIES L.C. (US) | 2014-11-25 | — | — | US | disclosed |
| US-8895752-B2 | Alkylsulfonyl-substituted thiazolide compounds | ROMARK LABORATORIES L.C. (US) | 2014-11-25 | — | — | US | disclosed |
| US-20120122939-A1 | ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS | ROMARK LABORATORIES, L.C. | 2012-05-17 | — | — | US | disclosed |
| US-8124632-B2 | Alkylsulfonyl-substituted thiazolide compounds | ROMARK LABORATORIES, L.C. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20090036467-A1 | ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS | ROMARK LABORATORIES L.C. | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122939-A1 | ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS | HAVCR2, EIF2AK2, AADAC | GRM4 4380/4885STAT3 63/4885MEN1 4564/4885 |
| US-20090036467-A1 | ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS | HAVCR2, EIF2AK2, AADAC | GRM4 4380/4885STAT3 63/4885MEN1 4564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.